Gadoxetic acid

Gadoxetic acid
Clinical data
Trade names	Eovist
Other names	Gadoxetate disodium (USAN US)
AHFS/Drugs.com	International Drug Names
ATC code	V08CA10 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 2-[[2-[bis(2-oxido-2-oxoethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(+3) cation;
CAS Number	135326-11-3 ;
PubChem CID	131704314;
DrugBank	DB08884 ;
ChemSpider	189907;
UNII	3QJA87N40S;
KEGG	D08008 ; D04288;
ChEMBL	ChEMBL1201768 ;
CompTox Dashboard (EPA)	DTXSID90928961 ;
Chemical and physical data
Formula	C23H30GdN3O11
Molar mass	681.75 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOc1ccc(cc1)C[C@@H](CN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Gd+3];
	InChI InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3/p-3/t17-;/m0./s1; Key:PCZHWPSNPWAQNF-LMOVPXPDSA-K;
	(what is this?) (verify)

Gadoxetic acid is a gadolinium-based MRI contrast agent.^[4] Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals.^[2]^[5]

Medical uses

It is used to increase the T1 signal intensity while imaging the liver lesions such as benign cysts, hemangioma, and liver cancer. It is excreted into bile by active secretion.^[6]

Pharmacokinetics

In those with end-stage renal failure, the clearance rate is only 17% with terminal half-life of 12 times longer than those with normal renal function.^[6]

References

^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 13 July 2024.
^ ^a ^b "Eovist- gadoxetate disodium injection, solution". DailyMed. National Library of Medicine, National Institutes of Health, U.S. Health & Human Services. Retrieved 21 April 2021.
^ "Active substance(s): gadoxetic acid disodium" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 14 January 2021.
^ Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. (August 2021). "Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging". European Radiology. 31 (8): 5615–5628. doi:10.1007/s00330-020-07637-4. PMC 8270799. PMID 33523304.
^ "Eovist - Homepage". Archived from the original on 25 April 2009. Retrieved 22 March 2009.
^ ^a ^b "Clinical pharmacology and biopharmaceutics review" (PDF). Center for drug evaluation and research. Archived from the original (PDF) on 12 May 2021. Retrieved 15 December 2022.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 13 July 2024.

[Eovist_FDA_label-2] "Eovist- gadoxetate disodium injection, solution". DailyMed. National Library of Medicine, National Institutes of Health, U.S. Health & Human Services. Retrieved 21 April 2021.

[3] "Active substance(s): gadoxetic acid disodium" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 14 January 2021.

[Koh_2021-4] Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. (August 2021). "Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging". European Radiology. 31 (8): 5615–5628. doi:10.1007/s00330-020-07637-4. PMC 8270799. PMID 33523304.

[bayer-5] "Eovist - Homepage". Archived from the original on 25 April 2009. Retrieved 22 March 2009.

[FDA-6] "Clinical pharmacology and biopharmaceutics review" (PDF). Center for drug evaluation and research. Archived from the original (PDF) on 12 May 2021. Retrieved 15 December 2022.

[1]

[2]

[3]

[4]

[5]

[6]